CNS Drugs

, Volume 23, Issue 3, pp 193–212

Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia

  • Pierre Thomas
  • Köksal Alptekin
  • Mihai Gheorghe
  • Mauro Mauri
  • José Manuel Olivares
  • Michael Riedel
Review Article


The initial management of patients with schizophrenia presenting to psychiatric emergency departments with an acute psychotic episode requires rapid decisions to be made by physicians concerning the treatment of individuals who are likely to be relatively uncooperative, agitated and lacking insight. The treatment decision must be adapted to the individual characteristics and needs of each patient. This article reviews the issues from the perspective of the initial management of acute psychosis as it is currently practised in Europe, and discusses the pragmatic implications for initial treatment decisions and the elaboration of a long-term treatment plan. Initially, administration of antipsychotics to control psychotic symptoms and benzodiazepines to control agitation represents the cornerstone of treatment. Oral medication is preferable to injectable forms wherever possible, and atypical antipsychotics are to be preferred over conventional agents because of their lower risk of extrapyramidal adverse effects, which are a major determinant of poor adherence to treatment. Whatever antipsychotic is chosen by the physician during the initial period, it is likely that it will need to be continued for many years, and it is thus important to take into account the long-term safety profile of the drug chosen, particularly in relation to extrapyramidal adverse effects, metabolic complications and quality of life. Building a therapeutic alliance with the patient and his/her family or carers is an important element that should be included in the initial management of psychosis. The long-term goal should be to minimize the risk of psychotic relapse through adequate treatment adherence.


  1. 1.
    American Psychiatric Association. American Psychiatric Association practice guidelines: practice guideline for the treatment of patients with schizophrenia: 2nd ed., 2004 [online]. Available from URL: [Accessed 2008 Feb 26]
  2. 2.
    Allen MH, Currier GW, Hughes DH, et al. The expert consensus guideline series: treatment of behavioral emergencies. Postgrad Med 2001 May; Spec. No.: 1-88; quiz 9-90Google Scholar
  3. 3.
    NICE. Clinical guidelines: schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care 2002 [online]. Available from URL: [Accessed 2008 Feb 26]
  4. 4.
    Fédération Française de Psychiatrie. Schizophrénies débutantes: diagnostic et modalités thérapeutiques — conference de consensus 2003 [online]. Available from URL: [Accessed 2008 Feb 26]
  5. 5.
    Gaebel W. S3-Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1: Behandlungsleitlinie Schizophrenie. Darmstad: Steinkopff Verlag, 2006Google Scholar
  6. 6.
    Sociedad Española de Psiquiatría. Consenso Español de Expertos para Recomendaciones de Actuación en el Tratamiento de la Esquizofrenia 2000 [online]. Available from URL: [Accessed 2009 Jan 16]
  7. 7.
    Turkish Psychiatric Association. Schizophrenia guidelines 2005 [online]. Available from URL: [Accessed 2008 Jan 14]
  8. 8.
    Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia: part 1. Acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6(3): 132–91PubMedCrossRefGoogle Scholar
  9. 9.
    Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998 Nov; 43Suppl. 2: 25–40SGoogle Scholar
  10. 10.
    Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 2004 Feb; 161(2 Suppl.): 1–56PubMedGoogle Scholar
  11. 11.
    Battaglia J. Pharmacological management of acute agitation. Drugs 2005; 65(9): 1207–22PubMedCrossRefGoogle Scholar
  12. 12.
    Ballerini A, Boccalon R, Boncompagni G, et al. An observational study in psychiatric acute patients admitted to general hospital psychiatric wards in Italy. Ann Gen Psychiatry 2007; 6: 2PubMedCrossRefGoogle Scholar
  13. 13.
    Ballerini A, Boccalon RM, Boncompagni G, et al. Main clinical features in patients at their first psychiatric admission to Italian acute hospital psychiatric wards: the PERSEO study. BMC Psychiatry 2007; 7: 3PubMedCrossRefGoogle Scholar
  14. 14.
    Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry 2006; 67Suppl. 10: 13–21PubMedGoogle Scholar
  15. 15.
    Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991 Jun; 148(6): 714–26PubMedGoogle Scholar
  16. 16.
    Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007 Jan; 13(1): 13–24PubMedCrossRefGoogle Scholar
  17. 17.
    Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16(1): 23–45PubMedCrossRefGoogle Scholar
  18. 18.
    American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinology, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27(2): 596–601CrossRefGoogle Scholar
  19. 19.
    Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19Suppl. 1: 1–93PubMedGoogle Scholar
  20. 20.
    Gury C, Canceil O, Iaria P. Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia [in French]. Encephale 2000 Nov–Dec; 26(6): 62–72PubMedGoogle Scholar
  21. 21.
    Geodon [package insert]. Ziprasidone summary of product characteristics: New York (NY): Pfizer, 2002 [online]. Available from URL: [Accessed 2008 Feb 25]
  22. 22.
    Serdolect (Sertindole) summary of product characteristics. Lundbeck, 2005 Sep 7 [online]. Available from URL: [Accessed 2009 Jan 15]
  23. 23.
    Sharif ZA. Overview of safety and tolerability of atypical antipsychotics used in primary care: primary care companion. J Clin Psychiatry 2003; 5Suppl. 3: 14–21Google Scholar
  24. 24.
    Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001 Nov; 23(11): 1839–54PubMedCrossRefGoogle Scholar
  25. 25.
    Riedel M, Muller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2005 Dec; 255(6): 432–7PubMedCrossRefGoogle Scholar
  26. 26.
    Risperidone. Summary of product characteristics, UK. Janssen-Cilag Ltd, 2008 Dec [online]. Available from URL: [Accessed 2009 Jan 14]
  27. 27.
    Quetiapine. Summary of product characteristics, UK. AstraZeneca UK Ltd, 2008 Dec [online]. Available from URL: [Accessed 2009 Jan 14]
  28. 28.
    Kapur S, Agid O, Mizrahi R, et al. How antipsychotics work-from receptors to reality. NeuroRx 2006 Jan; 3(1): 10–21PubMedCrossRefGoogle Scholar
  29. 29.
    Farde L, Wiesel FA, Halldin C, et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988 Jan; 45(1): 71–6PubMedCrossRefGoogle Scholar
  30. 30.
    Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopa-mine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992 Jul; 49(7): 538–44PubMedCrossRefGoogle Scholar
  31. 31.
    Nuss P, Hummer M, Tessier C. The use of amisulpride in the treatment of acute psychosis. Ther Clin Risk Manag 2007; 3(1): 3–11PubMedCrossRefGoogle Scholar
  32. 32.
    Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002 Dec; 63(12): 1121–8PubMedCrossRefGoogle Scholar
  33. 33.
    Marder SR. Evidence for using atypical antipsychotics in psychosis: primary care companion. J Clin Psychiatry 2003; 5Suppl. 3: 22–6Google Scholar
  34. 34.
    Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002; 16(7): 473–84PubMedCrossRefGoogle Scholar
  35. 35.
    Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002 Jan 3; 346(1): 16–22PubMedCrossRefGoogle Scholar
  36. 36.
    Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005 May; 162(5): 947–53PubMedCrossRefGoogle Scholar
  37. 37.
    Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353(12): 1209–23PubMedCrossRefGoogle Scholar
  38. 38.
    Hiemke C, Dragicevic A, Grunder G, et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004 Apr; 26(2): 156–60PubMedCrossRefGoogle Scholar
  39. 39.
    Muller MJ, Regenbogen B, Hartter S, et al. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 2007 Oct; 41(8): 673–9PubMedCrossRefGoogle Scholar
  40. 40.
    Mauri MC, Steinhilber CP, Marino R, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 2005 Jan; 20(1): 55–60PubMedCrossRefGoogle Scholar
  41. 41.
    Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46(5): 359–88PubMedCrossRefGoogle Scholar
  42. 42.
    Riedel M, Schwarz MJ, Strassnig M, et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 2005 Aug; 255(4): 261–8PubMedCrossRefGoogle Scholar
  43. 43.
    Spina E, Avenoso A, Facciola G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 2001 Jan 1; 153(2): 238–43PubMedCrossRefGoogle Scholar
  44. 44.
    Peuskens J, Moller HJ, Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 2002 Aug; 12(4): 305–10PubMedCrossRefGoogle Scholar
  45. 45.
    Vanelle JM, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry 2006 Dec; 21(8): 523–30PubMedCrossRefGoogle Scholar
  46. 46.
    Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004; 18(4): 251–67PubMedCrossRefGoogle Scholar
  47. 47.
    Tollefson GD, Sanger TM, Beasley CM, et al. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998 Jun 1; 43(11): 803–10PubMedCrossRefGoogle Scholar
  48. 48.
    Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety 2004; 20(1): 44–7PubMedCrossRefGoogle Scholar
  49. 49.
    Peuskens J, Van Baelen B, De Smedt C, et al. Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 2000 Nov; 15(6): 343–9PubMedCrossRefGoogle Scholar
  50. 50.
    Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 2000; 61Suppl. 14: 11–20PubMedGoogle Scholar
  51. 51.
    Allen MH, Currier GW. Use of restraints and pharma-cotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry 2004 Jan–Feb; 26(1): 42–9PubMedCrossRefGoogle Scholar
  52. 52.
    Brookes J. The incidence, severity and nature of violent incidents in the emergency department. Emerg Med Aust 1997; 9(1): 5–9CrossRefGoogle Scholar
  53. 53.
    Hill S, Petit J. The violent patient. Emerg Med Clin N Am 2000 May; 18(2): 301–15CrossRefGoogle Scholar
  54. 54.
    Mintzer JE. The clinical impact of agitation in various psychiatric disorders: management consensus and controversies. J Clin Psychiatry 2006; 67Suppl. 10: 3–5PubMedGoogle Scholar
  55. 55.
    Sailas E, Fenton M. Seclusion and restraint for people with serious mental illnesses. Cochrane Database Sys Rev 2000;(2):CD001163Google Scholar
  56. 56.
    Soyka M, Ufer S. Aggressiveness in schizophrenia: prevalence, psychopathological and sociodemographic correlates [in German]. Fortschritte der Neurologie-Psychiatrie 2002 Apr; 70(4): 171–7PubMedCrossRefGoogle Scholar
  57. 57.
    Olanzapine. Summary of product characteristics, UK. Eli Lilly and Company Ltd, 2008 Jul [online]. Available from URL:, [Accessed 2009 Jan 14]
  58. 58.
    Currier GW, Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract 2006 Jan; 12(1): 30–40PubMedCrossRefGoogle Scholar
  59. 59.
    Casey DE, Daniel DG, Wassef AA, et al. Effect of dival-proex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuro-psychopharmacology 2003 Jan; 28(1): 182–92Google Scholar
  60. 60.
    Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999 Mar; 56(3): 241–7PubMedCrossRefGoogle Scholar
  61. 61.
    Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002 Dec; 63(12): 1121–8PubMedCrossRefGoogle Scholar
  62. 62.
    Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003 Aug; 160(8): 1396–404PubMedCrossRefGoogle Scholar
  63. 63.
    Keefe RS, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004 Jun; 161(6): 985–95PubMedCrossRefGoogle Scholar
  64. 64.
    Harvey PD, Rabinowitz J, Eerdekens M, et al. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005 Oct; 162(10): 1888–95PubMedCrossRefGoogle Scholar
  65. 65.
    Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007 Jul; 164(7): 1061–71PubMedCrossRefGoogle Scholar
  66. 66.
    Harvey PD, Siu CO, Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology 2004 Mar; 172(3): 324–32PubMedCrossRefGoogle Scholar
  67. 67.
    Harvey PD, Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 2004 Feb 1; 66(2–3): 101–13PubMedCrossRefGoogle Scholar
  68. 68.
    Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001 Apr; 158(4): 518–26PubMedCrossRefGoogle Scholar
  69. 69.
    Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003 Jun; 60(6): 553–64PubMedCrossRefGoogle Scholar
  70. 70.
    Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000 Dec 2; 321(7273): 1371–6PubMedCrossRefGoogle Scholar
  71. 71.
    Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999 Jan 4; 35(1): 51–68PubMedCrossRefGoogle Scholar
  72. 72.
    Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002 Feb; 159(2): 180–90PubMedCrossRefGoogle Scholar
  73. 73.
    Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999; 25(4): 721–9PubMedCrossRefGoogle Scholar
  74. 74.
    Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999 Jan; 156(1): 79–87PubMedGoogle Scholar
  75. 75.
    Bobes J, Gibert J, Ciudad A, et al. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 2003 May; 27(3): 473–81PubMedCrossRefGoogle Scholar
  76. 76.
    Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, et al. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 2006 Oct; 67(10): 1511–21PubMedCrossRefGoogle Scholar
  77. 77.
    Robinson DG, Woerner MG, Delman HM, et al. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005 Jul; 31(3): 705–22PubMedCrossRefGoogle Scholar
  78. 78.
    McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007 Jul; 164(7): 1050–60PubMedCrossRefGoogle Scholar
  79. 79.
    Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008 Mar 29; 371(9618): 1085–97PubMedCrossRefGoogle Scholar
  80. 80.
    McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991 Aug; 48(8): 739–45PubMedCrossRefGoogle Scholar
  81. 81.
    IPAP. Schizophrenia algorithm: initial dosing and clinical titration of antipsychotics drugs in schizophrenia 2006 [online]. Available from URL: [Accessed 2008 Feb 26]
  82. 82.
    Wetterling T. Type 2 diabetes and dyslipidemia: side effects of “atypical” neuroleptics? [in German]. Med Klin (Munich) 2003 Jul 15; 98(7): 364–7CrossRefGoogle Scholar
  83. 83.
    Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005 Mar; 62(3): 247–53PubMedCrossRefGoogle Scholar
  84. 84.
    Dassori AM, Mezzich JE, Keshavan M. Suicidal indicators in schizophrenia. Acta Psychiatr Scand 1990 May; 81(5): 409–13PubMedCrossRefGoogle Scholar
  85. 85.
    Montross LP, Zisook S, Kasckow J. Suicide among patients with schizophrenia: a consideration of risk and protective factors. Ann Clin Psychiatry 2005 Jul–Sep; 17(3): 173–82PubMedCrossRefGoogle Scholar
  86. 86.
    Pompili M, Amador XF, Girardi P, et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry 2007; 6: 10PubMedCrossRefGoogle Scholar
  87. 87.
    Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005 Jul; 187: 9–20PubMedCrossRefGoogle Scholar
  88. 88.
    Meltzer HY. Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial. J Clin Psychiatry 1999; 60Suppl. 12: 47–50Google Scholar
  89. 89.
    Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003 Jan; 60(1): 82–91PubMedCrossRefGoogle Scholar
  90. 90.
    Fialko L, Freeman D, Bebbington PE, et al. Understanding suicidal ideation in psychosis: findings from the Psychological Prevention of Relapse in Psychosis (PRP) trial. Acta Psychiatr Scand 2006 Sep; 114(3): 177–86PubMedCrossRefGoogle Scholar
  91. 91.
    Zisook S, Byrd D, Kuck J, et al. Command hallucinations in outpatients with schizophrenia. J Clin Psychiatry 1995 Oct; 56(10): 462–5PubMedGoogle Scholar
  92. 92.
    Harkavy-Friedman JM, Kimhy D, Nelson EA, et al. Suicide attempts in schizophrenia: the role of command auditory hallucinations for suicide. J Clin Psychiatry 2003 Aug; 64(8): 871–4PubMedCrossRefGoogle Scholar
  93. 93.
    Farrell M, Howes S, Taylor C, et al. Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Int Rev Psychiatry 2003 Feb–May; 15(1–2): 43-9Google Scholar
  94. 94.
    Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997 Apr; 54(4): 313–21PubMedCrossRefGoogle Scholar
  95. 95.
    Dervaux A, Bayle FJ, Krebs MO. Substance misuse among people with schizophrenia: similarities and differences between the UK and France [letter]. Br J Psychiatry 2002 Apr; 180: 381PubMedCrossRefGoogle Scholar
  96. 96.
    Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004 Feb 1; 66(2-3): 125–35PubMedCrossRefGoogle Scholar
  97. 97.
    Dervaux A, Laqueille X, Bourdel MC, et al. Cannabis and schizophrenia: demographic and clinical correlates [in French]. Encephale 2003 Jan–Feb; 29(1): 11–7PubMedGoogle Scholar
  98. 98.
    Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002 Oct; 63(10): 892–909PubMedCrossRefGoogle Scholar
  99. 99.
    Viejo LF, Morales V, Punal P, et al. Risk factors in neuroleptic malignant syndrome: a case-control study. Acta Psychiatr Scand 2003 Jan; 107(1): 45–9PubMedCrossRefGoogle Scholar
  100. 100.
    Serrano-Duenas M. Neuroleptic malignant syndrome-like, or dopaminergic malignant syndrome, due to levodopa therapy withdrawal: clinical features in 11 patients. Parkinsonism Relat Disord 2003 Jan; 9(3): 175–8PubMedCrossRefGoogle Scholar
  101. 101.
    Tsuang J, Fong TW. Treatment of patients with schizophrenia and substance abuse disorders. Curr Pharmaceut Design 2004; 10(18): 2249–61CrossRefGoogle Scholar
  102. 102.
    Green AI. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. J Clin 0Psychiatry 2006; 67 Suppl. 7: 31–5; quiz 6-7Google Scholar
  103. 103.
    Potvin S, Stip E, Lipp O, et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 2006 Jul; 22(7): 1277–85PubMedCrossRefGoogle Scholar
  104. 104.
    Stuyt EB, Sajbel TA, Allen MH. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am J Addict 2006 Mar–Apr; 15(2): 166–73PubMedCrossRefGoogle Scholar
  105. 105.
    Dervaux A, Cazali J. Clozapine and amisulpride in refractory schizophrenia and alcohol dependence. J Clin Psychopharmacol 2007 Oct; 27(5): 514–6PubMedCrossRefGoogle Scholar
  106. 106.
    McEvoy J, Freudenreich O, McGee M, et al. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995 Apr 15; 37(8): 550–2PubMedCrossRefGoogle Scholar
  107. 107.
    Lee ML, Dickson RA, Campbell M, et al. Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry 1998 Oct; 43(8): 855–6PubMedGoogle Scholar
  108. 108.
    Buckley P, McCarthy M, Chapman P, et al. Clozapine treatment of comorbid substance abuse in patients with schizophrenia [abstract]. Schizophr Res 1999; 36: 272Google Scholar
  109. 109.
    McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999 Jul 1; 46(1): 125–9PubMedCrossRefGoogle Scholar
  110. 110.
    Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26(2): 441–9PubMedCrossRefGoogle Scholar
  111. 111.
    Zimmet SV, Strous RD, Burgess ES, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000 Feb; 20(1): 94–8PubMedCrossRefGoogle Scholar
  112. 112.
    Green AI, Burgess ES, Dawson R, et al. Alcohol and cannabis use in schizophrenia: effects of clozapine versus risperidone. Schizophr Res 2003 Mar 1; 60(1): 81–5PubMedCrossRefGoogle Scholar
  113. 113.
    Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006 Oct; 32(4): 637–43PubMedCrossRefGoogle Scholar
  114. 114.
    Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006 Oct 12; 355(15): 1525–38PubMedCrossRefGoogle Scholar
  115. 115.
    FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances, 2005 Apr 11 [online]. Available from URL: [Accessed 2008 Feb 26]
  116. 116.
    Avorn J, Bohn RL, Mogun H, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 1995 Jul; 99(1): 48–54PubMedCrossRefGoogle Scholar
  117. 117.
    Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995 Sep; 52(9): 756–65PubMedCrossRefGoogle Scholar
  118. 118.
    Barak Y, Shamir E, Weizman R. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. J Clin Psychopharmacol 2002 Apr; 22(2): 115–20PubMedCrossRefGoogle Scholar
  119. 119.
    Riedel M, Eich FX, Moller HJ. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. Eur Psychiatry. Epub 2008 Dec 12Google Scholar
  120. 120.
    Ritchie CW, Chiu E, Harrigan S, et al. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. Int J Geriatr Psychiatry 2006 Feb; 21(2): 171–9PubMedCrossRefGoogle Scholar
  121. 121.
    Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J Clin Psychiatry 2002; 63 Suppl. 13: 21–6PubMedGoogle Scholar
  122. 122.
    Alexopoulos GS, Streim J, Carpenter D, et al. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65Suppl. 2: 5–99; discussion 100-2; quiz 3-4PubMedGoogle Scholar
  123. 123.
    Politis AM, Papadimitriou GN, Theleritis CG, et al. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2008 Jul 1; 32(5): 1227–30PubMedCrossRefGoogle Scholar
  124. 124.
    McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004; 18(13): 933–56PubMedCrossRefGoogle Scholar
  125. 125.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999 Jan; 47(1): 30–9PubMedGoogle Scholar
  126. 126.
    Baldwin D. Psychotropic drugs and sexual dysfunction. Int Rev Psychiatry 1995; 7: 261–73CrossRefGoogle Scholar
  127. 127.
    Olfson M, Uttaro T, Carson WH, et al. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry 2005 Mar; 66(3): 331–8PubMedCrossRefGoogle Scholar
  128. 128.
    Rosenberg KP, Bleiberg KL, Koscis J, et al. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther 2003 Jul–Aug; 29(4): 289–96PubMedCrossRefGoogle Scholar
  129. 129.
    Lambert M, Conus P, Eide P, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004 Nov; 19(7): 415–22PubMedCrossRefGoogle Scholar
  130. 130.
    Arato M, Erdos A, Polgar M. Endocrinological changes in patients with sexual dysfunction under long-term neuroleptic treatment. Pharmakopsychiatr Neuropsychopharmakol 1979 Nov; 12(6): 426–31PubMedGoogle Scholar
  131. 131.
    Chen EY, Lee AS. Neuroleptic-induced priapism, hepatotoxicity and subsequent impotence in a patient with depressive psychosis. Br J Psychiatry 1990 Nov; 157: 759–62PubMedCrossRefGoogle Scholar
  132. 132.
    Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptictreated schizophrenic outpatients. J Nerv Mental Dis 1982 Aug; 170(8): 463–7CrossRefGoogle Scholar
  133. 133.
    Hummer M, Kemmler G, Kurz M, et al. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry 1999 Apr; 156(4): 631–3PubMedGoogle Scholar
  134. 134.
    Martin-Du Pan R. Neuroleptics and sexual dysfunction in man: neuroendocrine aspects [in German]. Schweiz Arch Neurol Neurochirurg Psychiatr 1978; 122(2): 285–313Google Scholar
  135. 135.
    Mitchell JE, Popkin MK. Antipsychotic drug therapy and sexual dysfunction in men [in German]. Am J Psychiatry 1982 May; 139(5): 633–7PubMedGoogle Scholar
  136. 136.
    Montejo AL. Antipsicóticos y afectación de la respuesta sexual. In: Bobes J, Dexeus S, Gibert J, editors. Psicofármacos y función sexual. Madrid: Ediciones Díaz de Santos; 1999: 111–32Google Scholar
  137. 137.
    Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004; 20(2): 189–97PubMedCrossRefGoogle Scholar
  138. 138.
    Byerly M, Suppes T, Tran QV, et al. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007 Dec; 27(6): 639–61PubMedCrossRefGoogle Scholar
  139. 139.
    Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002 Dec; 27(6): 1071–81PubMedCrossRefGoogle Scholar
  140. 140.
    Crosignani PG. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 2006 Apr 1; 125(2): 152–64PubMedCrossRefGoogle Scholar
  141. 141.
    Abraham G, Friedman RH, Verghese C. Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients. Biol Psychiatry 1996 Sep 1; 40(5): 430–1PubMedCrossRefGoogle Scholar
  142. 142.
    Hummer M, Malik P, Gasser RW, et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005 Jan; 162(1): 162–7PubMedCrossRefGoogle Scholar
  143. 143.
    Meyer JM, Lehman D. Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry 2006 Jan–Mar; 18(1): 43–8PubMedCrossRefGoogle Scholar
  144. 144.
    O’Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005 Feb; 25(1): 26–31PubMedCrossRefGoogle Scholar
  145. 145.
    Dalton SO, Johansen C, Poulsen AH, et al. Cancer risk among users of neuroleptic medication: a population-based cohort study. Br J Cancer 2006 Oct 9; 95(7): 934–9PubMedCrossRefGoogle Scholar
  146. 146.
    Goffin V, Touraine P, Culler MD, et al. Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperpro-lactinemia? Nat Clin Pract Endocrinol Metab 2006 Oct; 2(10): 571–81PubMedCrossRefGoogle Scholar
  147. 147.
    Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract 2003 Sep; 9(5): 344–53PubMedCrossRefGoogle Scholar
  148. 148.
    Wang PS, Walker AM, Tsuang MT, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002 Dec; 59(12): 1147–54PubMedCrossRefGoogle Scholar
  149. 149.
    Perkins D. Prolactin- and endocrine-related disorders in schizophrenia. In: Meyer JM, Nasrallah HA, editors. Medical illness and schizophrenia. Washington, DC: American Psychiatric Publishing, Inc., 2003; 215–32Google Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Pierre Thomas
    • 1
  • Köksal Alptekin
    • 2
  • Mihai Gheorghe
    • 3
  • Mauro Mauri
    • 4
  • José Manuel Olivares
    • 5
  • Michael Riedel
    • 6
  1. 1.Department of PsychiatryUniversity of Lille Medical SchoolLilleFrance
  2. 2.Department of PsychiatrySchool of Medicine, Dokuz Eylul UniversityIzmirTurkey
  3. 3.Department of PsychiatryClinical Central Military HospitalBucharestRomania
  4. 4.Department of Clinical PsychiatryUniversity of MilanMilanItaly
  5. 5.Department of PsychiatryVigo University HospitalPontevedraSpain
  6. 6.Department of Psychiatry and PsychotherapyLudwig-Maximilian UniversityMunichGermany
  7. 7.Pôle de PsychiatrieHopital M. Fontan, CHRU de LilleLille, CedexFrance

Personalised recommendations